Insperity (NSP) Q2 2025 earnings review
Profits Collapse on Soaring Benefit Costs; FY25 Guidance Cut Again as Focus Shifts to 2026
Insperity missed its Q2 guidance as soaring healthcare costs crushed profitability. While revenue grew a modest 3% YoY, gross profit plummeted 14% due to higher-than-expected pharmacy and large claim expenses, causing Adjusted EPS to fall 70% YoY to $0.26. Consequently, management cut its full-year adjusted EPS guidance for the second consecutive quarter, now expecting a ~40% YoY decline at the midpoint. The company is attempting to pivot the narrative to a 2026 recovery, driven by pricing actions and the planned beta launch of 'Insperity HRScale,' its new strategic partnership solution with Workday.
🐂 Bull Case
The strategic partnership with Workday, 'Insperity HRScale,' has a target go-live date for beta clients in early 2026. This is the cornerstone of the long-term growth story, aimed at expanding the addressable market and improving large-client retention.
Management has implemented a three-pronged plan to recover margins: increasing pricing for new and renewing clients, implementing benefit plan design changes for 2026, and renegotiating its contract with UHC.
🐻 Bear Case
The business model is currently failing to manage or price for rising healthcare costs. Gross profit per worksite employee per month fell 15% YoY from $282 to $240, indicating a fundamental profitability challenge.
Full-year 2025 adjusted EPS guidance has been slashed twice, from a midpoint of $3.53 in February to $2.16 today, a 39% reduction in six months. This pattern of missing and lowering guidance erodes investor confidence.
⚖️ Verdict: 🔴
Bearish. The magnitude of the earnings miss and repeated guidance cuts is alarming, suggesting management lacks visibility and control over its largest cost item. The Workday partnership is a promising long-term catalyst, but it's a 'jam tomorrow' story that cannot offset the severe deterioration in current profitability and management credibility.
Key Themes
Benefits Costs Overrun Destroys Profitability
The core issue this quarter was a severe spike in benefits costs, which rose 9.6% per covered employee YoY. Management attributed this to elevated pharmacy trends (including specialty drugs like GLP-1s) and higher frequency of large claims. This cost pressure directly caused a 15% YoY drop in Gross Profit per worksite employee per month, wiping out profitability despite stable revenue. This is the second consecutive quarter of higher-than-expected benefits costs, contradicting the narrative of a well-managed business.
Workday Partnership ('Insperity HRScale') Nears Launch
Management heavily emphasized progress on its strategic partnership with Workday. The joint solution has been branded 'Insperity HRScale' and has a target go-live date for beta clients in early 2026. The company completed market research that affirmed premium pricing potential for the offering. This initiative is key to the long-term strategy to expand into the mid-market and solve the 'success penalty' of clients outgrowing the current platform.
Repeated Guidance Cuts Erode Credibility
Management's ability to forecast the business has come into question. Since February 2025, the midpoint of full-year adjusted EPS guidance has been cut by 39%. The company also missed the low end of its Q2 EPS and EBITDA guidance provided just three months ago. This pattern suggests a poor grasp on underlying cost trends.
Proactive Margin Recovery Plan
In response to cost pressures, management is executing a three-part plan to restore profitability. This includes implementing higher pricing for new and renewing clients, making benefit plan design changes effective January 2026, and accelerating contract renewal discussions with its provider, UnitedHealthcare. The goal is to realign pricing and costs for a more profitable 2026.
Underlying Business Growth Remains Stable but Slow
Despite the severe profitability issues, the core client base remains stable. The average number of paid worksite employees (WSEEs) grew 1% YoY, and client retention was strong at 99% per month. Management noted that underlying WSEE counts have shown a 3% increase from a low point in February, suggesting some modest operational momentum.
Other KPIs
Decelerating. The company invested $14M in Q2, consistent with Q2 2024, but lower than the spend in late 2024. The full-year investment is guided to ~$58M. This remains a significant cash outlay with no revenue contribution expected until 2026, acting as a continued drag on near-term earnings.
Stable. The company returned $64M to shareholders YTD through $45M in dividends and $19M in share repurchases. While this signals confidence, the sustainability of buybacks could be questioned if profitability and cash flow continue to deteriorate.
Guidance
Decelerating. The midpoint of $2.16 implies a 39% decline from FY24's $3.58. This is the second major downward revision this year, confirming that the earnings recession is deeper than previously anticipated.
Decelerating. The midpoint of $0.275 implies a 30% decline from Q3 2024's result of $0.39. This indicates the severe earnings pressure will continue into the next quarter.
Stable. This guidance range is an update from the 0.5% - 3.0% range provided in Q1. It confirms that underlying unit growth remains positive but modest, providing a stable foundation but not enough to offset the margin collapse.
Decelerating. The midpoint ($187.5M) represents a 30% decline from FY24 ($270M) and is a significant reduction from the prior guidance of $190M-$245M.